RESUMEN
Peripheral blood progenitor cells (PBPC) were mobilised by recombinant human G-CSF (rhG-CSF) and cyclophosphamide, harvested by apheresis from 9 patients with NHL and stored at 4 degrees C without further manipulation. They were then reinfused after high-dose chemotherapy. We monitored the change in colony-forming units-granulocyte, macrophage (CFU-GM) proliferation as well as plasma glucose, lactate and pH levels over the period of the study. In an attempt to maintain CFU-GM numbers, rhG-CSF was added to storage bags at collection and 48 h later. Our observations suggest that cell viability is well maintained and that CFU-GM numbers rise over the first 48 h of storage before falling rapidly. Metabolic changes cause a fall in the pH and glucose levels with a reciprocal rise in plasma lactate. The addition of rhG-CSF at a concentration of 10 ng/ml to cells in storage showed no detectable benefit. Following storage for 96 h, 77% (SEM +/- 8%) of the initial CFU-GM remained.
Asunto(s)
Trasplante de Células Madre Hematopoyéticas/métodos , Eliminación de Componentes Sanguíneos , Supervivencia Celular , Factor Estimulante de Colonias de Granulocitos/farmacología , Hematopoyesis , Células Madre Hematopoyéticas/citología , Humanos , Concentración de Iones de Hidrógeno , Técnicas In Vitro , Conservación de Tejido/métodosRESUMEN
The results from 40 patients who have undergone autologous bone marrow transplantation (ABMT) for relapsed or refractory Hodgkin's disease between March 1988 and September 1992 have been analysed. In contrast to our results in patients with relapsed HD, our results in patients with refractory HD are comparatively poor. Conventional salvage chemotherapy also seems inappropriate in these patients and we therefore believe they should be offered high-dose chemotherapy before their disease becomes refractory to conventionally scheduled regimens. Peripheral blood stem cell (PBSC) transplant now offers an attractive alternative to ABMT and may replace both intensive salvage chemotherapy and ABMT as the optimum treatment for patients who fail to respond to conventional chemotherapy regimens.
Asunto(s)
Trasplante de Médula Ósea/estadística & datos numéricos , Enfermedad de Hodgkin/terapia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Trasplante de Médula Ósea/mortalidad , Terapia Combinada , Resistencia a Medicamentos , Femenino , Enfermedad de Hodgkin/mortalidad , Humanos , Tablas de Vida , Masculino , Pronóstico , Inducción de Remisión , Estudios Retrospectivos , Terapia Recuperativa , Análisis de Supervivencia , Resultado del TratamientoRESUMEN
A monoclonal antibody-derived, dry blood grouping plate, based upon the simple disaccharide, trehalose, is described that is indefinitely stable at room temperature and was found to have a 99.8% accuracy when tested against a standard semiautomated assay. This plate can be used by personnel with no specific training to check the recorded A,B,O, and Rhesus blood type of potential transfusion recipients in the field and at the bedside. Trehalose-based reagents may be important for bedside testing and in developing countries where refrigeration is unreliable.
Asunto(s)
Anticuerpos Monoclonales , Tipificación y Pruebas Cruzadas Sanguíneas/instrumentación , Inmunoglobulina M , Trehalosa , Pruebas de Aglutinación , Tipificación y Pruebas Cruzadas Sanguíneas/métodos , Países en Desarrollo , Almacenaje de Medicamentos/métodos , Estudios de Evaluación como Asunto , Humanos , Factores de TiempoRESUMEN
A case of severe intravascular haemolysis, due to an 'auto-anti-B antibody', and a case of transient haemolytic anaemia, due to an 'auto-anti-A antibody', following allogeneic organ transplantation, are reported. Both patients were receiving immunosuppressive therapy with cyclosporin A and were non-secretors of A, B and H substances.